Rodrigo Pessôa1, Ester C Sabino2, Sabri S Sanabani3,4. 1. Department of Pathology, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil. rodrigo_pessoa1@hotmail.com. 2. Department of Infectious Disease/Institute of Tropical Medicine, University of São Paulo, Sao Paulo, Brazil. sabinoec@gmail.com. 3. Department of Pathology, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil. sabyem_63@yahoo.com. 4. Medicina Instituto de Medicina Tropical de São Paulo, LIM 52 - Av. Dr. Enéas Carvalho de Aguiar, 470 - 2° andar - Cerqueira Cesar, 05403-000, Sao Paulo, SP, Brazil. sabyem_63@yahoo.com.
Abstract
BACKGROUND: The interaction of HIV-1 and target cells involves sequential binding of the viral gp120 Env protein to the CD4 receptor and a chemokine co-receptor (either CCR5 or CXCR4). CCR5 antagonists have proved to be an effective salvage therapy in patients with CCR5 using variants (R5) but not with variants capable of using CXCR4 (×4) phenotype. Thus, it is critically important to determine cellular tropism of a country's circulating HIV strains to guide a management decision to improve treatment outcome. In this study, we report the prevalence of R5 and ×4 HIV strains in 45 proviral DNA massively parallel sequencing "MPS" data from recently infected Brazilian blood donors. METHODS: The MPS data encompassing the tropism-related V3 loop region of the HIV-1 env gene was extracted from our recently published HIV-1 genomes sequenced by a paired-end protocol (Illumina). HIV-1 tropism was inferred using Geno2pheno[coreceptor] algorithm (3.5 % false-positive rate). V3 net charge and 11/25 rules were also used for coreceptor prediction. RESULTS: Among the 45 samples for which tropism were determined, 39 were exclusively R5 variants, 5 ×4 variants, and one dual-tropic or mixed (D/M) populations of R5 and ×4 viruses, corresponding to 86.7, 11.1 and 2.2 %, respectively. Thus, the proportion of all blood donors that harbor CXCR4-using virus was 13.3 % including individuals with D/M-tropic viruses. CONCLUSIONS: The presence of CCR5-tropic variants in more than 85 % of our cohort of antiretroviral-naïve blood donors with recent HIV-1 infection indicates a potential benefit of CCR5 antagonists as a therapeutic option in Brazil. Therefore, determination of viral co-receptor tropism is an important diagnostic prerequisite.
BACKGROUND: The interaction of HIV-1 and target cells involves sequential binding of the viral gp120Env protein to the CD4 receptor and a chemokine co-receptor (either CCR5 or CXCR4). CCR5 antagonists have proved to be an effective salvage therapy in patients with CCR5 using variants (R5) but not with variants capable of using CXCR4 (×4) phenotype. Thus, it is critically important to determine cellular tropism of a country's circulating HIV strains to guide a management decision to improve treatment outcome. In this study, we report the prevalence of R5 and ×4 HIV strains in 45 proviral DNA massively parallel sequencing "MPS" data from recently infected Brazilian blood donors. METHODS: The MPS data encompassing the tropism-related V3 loop region of the HIV-1env gene was extracted from our recently published HIV-1 genomes sequenced by a paired-end protocol (Illumina). HIV-1 tropism was inferred using Geno2pheno[coreceptor] algorithm (3.5 % false-positive rate). V3 net charge and 11/25 rules were also used for coreceptor prediction. RESULTS: Among the 45 samples for which tropism were determined, 39 were exclusively R5 variants, 5 ×4 variants, and one dual-tropic or mixed (D/M) populations of R5 and ×4 viruses, corresponding to 86.7, 11.1 and 2.2 %, respectively. Thus, the proportion of all blood donors that harbor CXCR4-using virus was 13.3 % including individuals with D/M-tropic viruses. CONCLUSIONS: The presence of CCR5-tropic variants in more than 85 % of our cohort of antiretroviral-naïve blood donors with recent HIV-1 infection indicates a potential benefit of CCR5 antagonists as a therapeutic option in Brazil. Therefore, determination of viral co-receptor tropism is an important diagnostic prerequisite.
Authors: Zabrina L Brumme; James Goodrich; Howard B Mayer; Chanson J Brumme; Bethany M Henrick; Brian Wynhoven; Jerome J Asselin; Peter K Cheung; Robert S Hogg; Julio S G Montaner; P Richard Harrigan Journal: J Infect Dis Date: 2005-06-23 Impact factor: 5.226
Authors: Ester C Sabino; Thelma T Gonçalez; Anna Bárbara Carneiro-Proietti; Moussa Sarr; João Eduardo Ferreira; Divaldo A Sampaio; Nanci A Salles; David J Wright; Brian Custer; Michael Busch Journal: Transfusion Date: 2011-10-07 Impact factor: 3.157
Authors: Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros Journal: J Virol Date: 2006-12-20 Impact factor: 5.103
Authors: G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso Journal: Nat Med Date: 1997-11 Impact factor: 53.440
Authors: Evelien M Bunnik; Luke C Swenson; Diana Edo-Matas; Wei Huang; Winnie Dong; Arne Frantzell; Christos J Petropoulos; Eoin Coakley; Hanneke Schuitemaker; P Richard Harrigan; Angélique B van 't Wout Journal: PLoS Pathog Date: 2011-06-23 Impact factor: 6.823
Authors: Nametso Kelentse; Sikhulile Moyo; Mompati L Mogwele; Doreen Ditshwanelo; Baitshepi Mokaleng; Natasha O Moraka; Kwana Lechiile; Tshepo B Leeme; David S Lawrence; Rosemary Musonda; Ishmael Kasvosve; Thomas S Harrison; Joseph N Jarvis; Simani Gaseitsiwe Journal: Viruses Date: 2020-12-07 Impact factor: 5.048